Interleukin-17A Gene Expression in Morbidly Obese Women

Fernando Zapata-Gonzalez 1,†, Teresa Auguet 1,2,†, Gemma Aragonès 1, Esther Guiu-Jurado 1, Alba Berlanga 1, Salomé Martínez 3, Andreu Martí 2, Fátima Sabench 4, Mercè Hernandez 4, Carmen Aguilar 1, Joan Josep Sirvent 3, Rosa Jorba 5, Daniel Del Castillo 4 and Cristóbal Richart 1,2,*

1 Grup de Recerca GEMMAIR (AGAUR)—Medicina Aplicada, Departament de Medicina i Cirurgia, Institut d’Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili (URV), 43007 Tarragona, Spain; E-Mails: fernandoa.zapata@gmail.com (F.Z.-G.); tauquet.hj23.ics@gencat.cat (T.A.); gemma.aragones@iispv.cat (G.A.); esther.guiu@urv.cat (E.G.-J.); alba.berlanga@urv.cat (A.B.); caguilar.hj23.ics@gencat.cat (C.A.)

2 Servei Medicina Interna, Hospital Universitari Joan XXIII Tarragona, Mallafrè Guasch, 4, 43007 Tarragona, Spain; E-Mail: andreuman@gmail.com

3 Servei Anatomia Patològica, Hospital Universitari Joan XXIII Tarragona, Mallafrè Guasch, 4, 43007 Tarragona, Spain; E-Mails: mgonzalez.hj23.ics@gencat.cat (S.M.); jsirvent.hj23.ics@gencat.cat (J.J.S.)

4 Servei de Cirurgia, Hospital Sant Joan de Reus, Departament de Medicina i Cirurgia, IISPV, Universitat Rovira i Virgili (URV), Avinguda Doctor Josep Laporte, 2, 43204 Tarragona, Spain; E-Mails: fatima.sabench@urv.cat (F.S.); mherandezg@grupsagessa.com (M.H.); ddelcastillo@grupsagessa.com (D.D.C.)

5 Servei de Cirurgia, Hospital Universitari Joan XXIII Tarragona, Mallafrè Guasch, 4, 43007 Tarragona, Spain; E-Mail: rjorba.hj23@gencat.cat

† These authors contributed equally to this work.

* Author to whom correspondence should be addressed; E-Mail: crichart.hj23.ics@gencat.cat; Tel./Fax: +34-977-295-833.

Academic Editor: Toshiro Arai

Received: 5 June 2015 / Accepted: 27 July 2015 / Published: 30 July 2015

Abstract: Data from recent studies conducted in rodent models and humans suggest that interleukin-17A (IL-17A) plays a role in the induction of inflammation in adipose tissue during obesity. The aim of this study was to assess the gene expression of IL-17A in adipose tissue of morbidly obese patients. We used RT-PCR to evaluate the expression of IL-17A

and several adipo/cytokines in the visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) of 10 normal-weight control women (BMI < 25 kg/m²) and 30 morbidly obese women (MO, BMI > 40 kg/m²). We measured serum levels of IL-17A and adipo/cytokines in MO and normal weight women. IL-17A expression was significantly higher in VAT than in SAT in MO patients \( (p = 0.0127) \). It was very low in normal-weight controls in both VAT and SAT tissues. We found positive correlations between IL-17A and IL-6, lipocalin-2 and resistin in VAT of MO patients. The circulating level of IL-17A was higher in the normal-weight group than the MO patients \( (p = 0.032) \), and it was significantly related to adiponectin and TNFRII levels. In conclusion, IL-17A expression in VAT is increased in morbidly obese women, which suggests a link between obesity and innate immunity in low-grade chronic inflammation in morbidly obese women.

**Keywords:** IL-17A; morbid obesity; adipo/cytokine; visceral adipose tissue

### 1. Introduction

Nowadays, obesity is perceived not only as an aesthetic drawback, but also as a serious, almost pandemic, health problem associated with an increased risk of developing such diseases as type 2 diabetes mellitus, metabolic syndrome, cardiovascular disease, cancer and autoimmune diseases [1]. Nutrient excess and adiposity activate several metabolic pathways implicated in the development of insulin resistance, including inflammatory signaling, lipotoxicity, aberrant adipokine secretion, adipose tissue hypoxia, endoplasmic reticulum stress and mitochondrial dysfunction [2–8]. Several of these metabolic processes can converge in the development of metabolic inflammation. The first indication that inflammatory mediators are associated with obesity was the discovery of the increased expression of the pro-inflammatory cytokine tumor necrosis factor (TNF) α in adipose tissue of obese mice almost two decades ago [9]. Subsequent studies have shown that changes in inflammatory signaling by adipocytes and infiltration of adipose tissue by immune cells are key features of obesity-induced insulin resistance and associated metabolic disease in animal models and humans [10–12]. In obese mice, both adipocytes and macrophages (and potentially other cell types) residing in adipose tissue secrete a number of cytokines, including TNFα, interleukin (IL)-6, IL-1β and migration inhibitory factor [11]. Increased expression of inflammatory mediators has also been observed in the visceral fat of obese humans and mice [13]. In this regard, obesity leads to a state of low-grade chronic inflammation in adipose tissues, with increased adipose tissue macrophage infiltration [14]. In addition to macrophages, other immune cells, including mediators of both innate and adaptive immune responses, also localize to adipose tissue in obesity [15]. Neutrophils, mast cells, natural killer T cells and lymphocytes have all been observed in white adipose tissue in response to a high-fat diet (HFD) or in conditions of obesity [16–19]. However, the precise point at which this infiltration occurs during disease progression and their pro-inflammatory cytokine production in the pathogenesis of metabolic dysfunction in obese people remains to be determined.

Unlike “classic” pro-inflammatory mediators, for example TNF-α, IL-6 and C-reactive protein, T cell-derived cytokines, such as IL-17A, have not been extensively investigated in obesity. Mainly
induced by monocyte/dendritic cell-derived IL-23, IL-17A has been implicated not only in host defense, but also in the pathogenesis of several autoimmune disorders and cancer [20]. It has recently been suggested that IL-17A plays a role in the induction of inflammation in adipose tissue during obesity, glucose homeostasis and adipogenesis [21]. Despite the fact that it has been reported that inflammatory cytokines, such as IL-17A regulates the differentiation of adipocytes and their capacity to secrete adipocytokines, the relationship between IL-17A and other adipocytokines is still unknown. Moreover, some studies have shown that serum IL-17A is upregulated in obese human patients [22]. Obesity is also positively correlated with increased IL-17A expression and increased severity of inflammation in IL-17A-dependent mouse models [23]. Although these studies suggest a link between obesity and IL-17, their pro-inflammatory cytokine role in the metabolic dysfunction of obese people is not completely understood.

On the basis of the above data and to better understand the mechanisms causing or maintaining the dysfunction of adipose tissue, the aim of the present study was to assess IL-17A in low-grade chronic inflammation due to obesity by: (1) evaluating the expression of IL-17A and several adipocytokines in both visceral (VAT) and subcutaneous adipose tissue (SAT); (2) analyzing the circulating levels of IL-17A and other adipocytokines from morbidly obese patients and normal-weight healthy subjects.

2. Results

2.1. Baseline Characteristics of Subjects

Table 1 shows the general characteristics, biochemical and metabolic measurements of the population studied. We classified the patients into two groups according to their body mass index (BMI): normal-weight patients (BMI < 25 kg/m²), who acted as controls and morbidly obese women (MO; BMI > 40 kg/m²). The two groups were comparable in terms of age (p = 0.442). As expected, biochemical analyses indicated that MO patients had significantly higher levels of fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA2-IR), glycated hemoglobin (HbA1c), systolic blood pressure (SBP) and diastolic blood pressure (DBP) (p < 0.05) than normal-weight subjects. There was no difference in lipid profile, because the morbidly obese women were taking lipid-lowering drugs.

| Variables     | Normal-Weight Control (n = 10) | Morbidly Obese (n = 30) |
|---------------|--------------------------------|-------------------------|
|               | Mean ± SD                       | Mean ± SD               |
| Age (years)   | 43.70 ± 12.35                  | 47.00 ± 7.35            |
| Weight (kg)   | 56.30 ± 8.64                   | 123.69 ± 13.18 *        |
| WC (cm)       | 68.60 ± 10.5                   | 135.16 ± 11.32 *        |
| BMI (kg/m²)   | 22.61 ± 1.91                   | 47.21 ± 5.4 *           |
| SBP (mmHg)    | 119.88 ± 13.08                 | 139.10 ± 14.78 *        |
| DBP (mmHg)    | 67.55 ± 7.57                   | 80.26 ± 14.76 *         |
| Glucose (mg/dL)| 88.11 ± 9.63                   | 115.5 ± 26.12 *         |
| Insulin (mU/L)| 7.93 ± 5.86                    | 20.26 ± 13.99 *         |
| HbA1c (%)     | 4.55 ± 0.28                    | 5.7 ± 1.22 *            |
### Table 1. Cont.

| Variables                        | Normal-Weight Control (n = 10) | Morbidly Obese (n = 30) |
|----------------------------------|-------------------------------|-------------------------|
|                                  | Mean ± SD                     | Mean ± SD               |
| HOMA2-IR                         | 1.07 ± 0.83                   | 2.69 ± 1.77 *           |
| Cholesterol (mg/dL)              | 172.68 ± 25.91                | 179.39 ± 35.22          |
| HDL-C (mg/dL)                    | 54.66 ± 17.85                 | 41.26 ± 7.52            |
| LDL-C (mg/dL)                    | 93.77 ± 26.74                 | 106.13 ± 28.64          |
| Triglycerides (mg/dL)            | 121 ± 79.32                   | 159.6 ± 53.25           |
| **Adipo/cytokine circulating levels** |                               |                         |
| Adiponectin (µg/mL)             | 11.48 ± 6.13                  | 6.77 ± 2.84 *           |
| IL-6 (pg/mL)                    | 1.78 ± 1.55                   | 2.95 ± 1.56             |
| Lipocalin-2 (ng/mL)             | 63.53 ± 28.33                 | 82.26 ± 29.85           |
| Resistin (ng/mL)                | 3.61 ± 1.31                   | 4.52 ± 1.63             |
| TNFRII (ng/mL)                  | 3.09 ± 1.51                   | 5.19 ± 2.37 *           |

WC, waist circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin; HOMA2-IR, homeostasis model assessment of insulin resistance; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein. * Significant differences compared to normal-weight controls (p < 0.05). Data are expressed as the mean ± SD.

#### 2.2. IL-17A and Adipo/Cytokine mRNA Expression in Adipose Tissue

First, we analyzed the expression of IL-17A in visceral and subcutaneous adipose tissue in both normal-weight patients and MO. IL-17A mRNA expression was very low (almost undetectable) in normal-weight controls in both VAT and SAT tissues (Figure 1A), whereas in MO patients, IL-17A expression was significantly higher in VAT than in SAT (p = 0.0127, Figure 1B).

![Figure 1. IL-17A mRNA expression in visceral and subcutaneous adipose tissues in normal-weight subjects (A) and morbidly obese women (B). AU: arbitrary units × 10⁴; VAT: visceral adipose tissue; SAT: subcutaneous adipose tissue. Student’s t-test was used to compare the gene expression in the two groups. Results are shown as the mean ± SD. p < 0.05 is considered statistically significant.](image-url)
In order to determine whether IL-17A can induce pro-inflammatory cytokine IL-6 secretion, we also evaluated IL-6 mRNA expression in both human adipose tissues in normal-weight subjects and MO. We found that IL-6 expression was higher in the VAT and SAT of MO women than in the normal-weight group (Table 2, \( p < 0.001 \)). In the MO group, there were no differences between VAT and SAT tissues.

| Gene Expression | Normal-Weight Control \((n = 10)\) | Morbidly Obese \((n = 30)\) |
|-----------------|-------------------------------|----------------------------|
|                 | VAT Mean ± SD | SAT Mean ± SD | VAT Mean ± SD | SAT Mean ± SD |
| IL-6            | 2.38 ± 1.52 | 17.07 ± 11.66 | 61.09 ± 14.13 * | 86.40 ± 28.71 * |
| Adiponectin     | 0.77 ± 0.32 | 0.58 ± 0.30  | 0.53 ± 0.27   | 0.29 ± 0.17 *  |
| Lipocalin-2     | 0.006 ± 0.003 | 0.029 ± 0.02 | 0.02 ± 0.01   | 0.064 ± 0.03   |
| TNF\( \alpha \)  | 0.039 ± 0.002 | 0.076 ± 0.06 | 0.26 ± 0.20 * | 0.043 ± 0.02   |
| Resistin        | 0.008 ± 0.004 | 0.016 ± 0.005 | 0.030 ± 0.02 * | 0.030 ± 0.02 |

Student’s \( t \)-test was used to compare the gene expression in the two groups. * Indicates significant differences with respect to the normal-weight group \(( p < 0.05 \)). The mRNA expression for each gene and sample was calculated using the recommended \( 2^{-\Delta\Delta C_t} \) method. Data are expressed as the mean ± SD.

As far as adipo/cytokine expression was concerned, we found that resistin and TNF\( \alpha \) were increased in the VAT of MO patients in comparison to normal-weight controls, whereas adiponectin was higher in the SAT control group (Table 2). In the MO group, we found positive correlations between IL-17A expression and IL-6, lipocalin-2 and resistin expressions in VAT tissue (Figure 2).

Figure 2. Correlation between mRNA expression of IL-17A and IL-6 (A), lipocalin-2 (B) and resistin (C) in visceral adipose tissue of morbidly obese women. The strength of association between variables was calculated using Spearman’s \( r \) correlation test. \( p < 0.05 \) is considered statistically significant.

2.3. IL-17A and Adipo/Cytokine Circulating Levels

In order to study whether the differences observed in mRNA expression were only a local effect or if they were also reflected in serum, we measured circulating levels in both groups. Figure 3 shows that the IL-17A serum concentration was higher in the normal-weight group than in the MO patients \(( p = 0.032 \)).
We also compared the circulating levels of adipokines in the MO group with controls (Table 1), and analyzed their association with serum IL-17A levels. As expected, we found that adiponectin circulating levels were higher in the normal-weight group than in the MO patients \( (p = 0.003) \). In contrast, we observed that TNFRII levels were significantly higher in MO patients than in normal-weight subjects \( (p = 0.019) \).

Then, we assessed the relationship between IL-17A and adipokines in serum. In the whole population studied, we found that IL-17A was positively related to adiponectin and inversely to TNFRII levels \( (r = 0.367, p = 0.028; r = -0.479, p = 0.004; \text{respectively}) \). In MO patients, these correlations were significant \( (r = 0.503, p = 0.007; r = -0.456, p = 0.019; \text{respectively}) \).

**Figure 3.** Circulating levels of IL-17A in normal-weight subjects (BMI < 25) and morbidly obese women (BMI > 40). Student’s \( t \)-test was used to compare the gene expression in the two groups. Results are shown as the mean ± SD. \( p < 0.05 \) are considered statistically significant.

### 3. Discussion

Recent studies showed the potential implication of IL-17A in human obesity-linked inflammation and co-morbidities [24–27]. Thus, we analyzed the gene expression of IL-17A and several adipokines in VAT and SAT samples from morbidly obese and normal-weight women. We also evaluated their circulating levels in both groups. We demonstrated that IL-17A mRNA expression was almost undetectable in normal-weight controls in both VAT and SAT tissues. However, IL-17A expression was significantly higher in VAT than in SAT in MO women. Paradoxically, we found that IL-17A serum levels were higher in the normal-weight women than in the MO women.

In many senses, obesity is considered to be an inflammatory predisposition. For instance, low levels of chronic inflammation and macrophage infiltration into adipose tissue are associated with obese conditions [28]. Obesity is also noted to predispose to several autoimmune disorders [29–31]. Although the mechanisms connecting both phenomena remain elusive, important recent evidence has suggested that IL-17A is a key element in these processes. Not only can it regulate adipogenesis and glucose homeostasis in murine obesity, but it is also associated with chronic inflammation processes and autoimmune disorders [20,21]. Recent studies have reported that CD4+ T cells are increased in adipose
tissue of overweight and obese patients [26,32]. In view of these previous data, we have been able to confirm that IL-17A is present in the adipose tissue of MO women. According to our results, Bertola et al. found that expression of IL-17A in the stromal vascular fraction from adipose tissue was increased in overweight and obese patients compared to lean subjects [32]. Surprisingly, we found that IL-17A expression was much lower than that of the housekeeping gene, especially in subcutaneous adipose tissue. This can be partially explained, at least in humans, by self-regulatory mechanisms that limit the expansion of TH17 cells (impaired IL-2 production and arrest of cell cycle progression) and the high transience of these cells, which rapidly shift to a Th1 profile [33]. Some recent studies have shown that obesity is directly related to IL-17A expression and increased severity of inflammation in IL-17A-dependent mouse models [23]. In rodent models, Zuñiga et al. [21] showed that IL-17 is expressed by γδ T cells in white adipose tissue. Interestingly, we observed that IL-17A expression is greater in VAT than in SAT. In this regard, fat stored in visceral adipose depots makes obese individuals more prone to metabolic complications than fat distributed subcutaneously [34]. Another important fact to note is that IL-17A mRNA expression was almost undetectable in normal-weight controls in both VAT and SAT tissues, which may be due to the lack of adipose tissue inflammation in this group of subjects [35].

It has been widely shown that IL-6 expands the TH17 fraction in obesity while being concurrently induced by IL-17A itself [36]. Our findings showed a positive correlation between IL-17A and IL-6 expression in the VAT of MO patients. IL-17A could be related to low-grade inflammation in obese patients, as it is capable of inducing other pro-inflammatory mediators, such as IL-6, and inducing neutrophil chemotaxis [36,37]. In this regard, it has been reported that IL-17A can stimulate the production of IL-6 by activating such signaling pathways as NF-κB, Stat3 or PI3K/Akt [38]. Thus, IL-17 is a cytokine-inducing cytokine, and the interaction between IL-17A and IL-6 can increase the levels of both cytokines. It is also known that IL-6 is required for the differentiation of naive CD4 T cells into the Th17 lineage [39,40] and is a major downstream gene target of IL-17A [41,42].

Furthermore, in VAT tissue, we found positive correlations between IL-17A and lipocalin-2, two adipose tissue-derived cytokines, and resistin expression. Lipocalin-2 seems to act as a dual molecule with regard to inflammation in obesity [43–45]. Increased adipose tissue expression of resistin has been previously described in obesity [46]. These and many other adipocytokines play a physiological and pro-inflammatory role in metabolism and are involved in the development of obesity, inflammation and auto-immune disorders [47].

As far as circulating levels are concerned, IL-17A is mainly secreted by the activated CD4+ and CD8+ T lymphocytes and has been classified as a pro-inflammatory cytokine because of its ability to induce the expression of many mediators of inflammation [48]. The morbidly obese women in our study had less IL-17 in the circulation than normal-weight controls. This finding did not coincide with that of a previous publication that reported increased IL-17A circulating levels in the plasma of obese women [22]. This inconsistency might stem from the dissimilarities in the populations studied in terms of age and obesity grade. It is known that aging is accompanied by a progressive increase in pro-inflammatory cytokines, including IL-17A [49]. In this sense, the cohort of Sumarac-Dumanovic et al. has an age of 35.0 ± 8.5 years [22]. However, our cohort of morbidly obese women was older. Regarding obesity grade, although it is not possible to determine the causality of the fact that the levels of IL-17A were decreased in serum of obese patients, the reported results suggest that in this type of
extreme obesity, adipose tissue behaves in a differential way than expected [13]. We also observed that IL-17A circulating levels were positively related to adiponectin and negatively to TNFRII levels, as was also observed by Xuan et al. [50]. Taken together, these results do not clarify whether IL-17A acts as a pro-inflammatory molecule. Further studies of IL-17A circulating levels are needed to understand these controversial results.

Our study cohort enabled us to confirm the expression of IL-17A in adipose tissue of the morbidly obese without the interference of such confounding factors as gender or age. However, the results of our study cannot be extrapolated to other obesity groups or to men. Furthermore, our findings indicate that there may be a late adaptive process in this type of extreme obesity.

4. Materials and Methods

4.1. Subjects

The study was approved by the institutional review board “Comitè d’Ètica d’Investigació Clínica, Hospital Universitari de Tarragona Joan XXIII” (6proj2; 25 June 2009). All participants gave written informed consent for participation in medical research. We analyzed gene expression in paired samples of subcutaneous and visceral adipose tissue from 40 women of Western European descent: 10 normal weight (BMI < 25 kg/m²) and 30 morbidly obese (BMI > 40 kg/m²). Adipose tissue samples were obtained from morbidly obese women who underwent bariatric surgery by laparoscopic gastric bypass and from lean patients who underwent laparoscopic cholecystectomy for benign gall bladder disease or laparoscopic hiatal hernia repair. Subcutaneous adipose tissue biopsies were taken from the right hypochondriac region, and visceral adipose tissue biopsies were taken from the greater epiploon region. Samples were obtained by the same specialist in each surgical case. Morbidly obese women and controls were similar age. The weight of all subjects had been stable for at least 3 months before surgery. Patients who had an acute illness, acute or chronic inflammatory or infective diseases, or end-stage malignant disease were excluded. Menopausal women and women receiving contraceptive treatment were also excluded.

4.2. Biochemical Analyses

The anthropometric and metabolic characteristics of the subjects were determined. Body height and weight were measured with the patient standing shoeless and in light clothes. BMI was calculated as body weight divided by height squared (kg/m²). Laboratory studies included glucose, insulin, HbA1c, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides, all of which were analyzed using a conventional automated analyzer. The homeostasis model assessment of insulin resistance (HOMA2-IR) was completed using the HOMA calculator version 2.2.2 [51].

4.3. RNA Isolation and Real-Time PCR

Total RNA was isolated from adipose tissues in accordance with the manufacturer’s protocol for the RNeasy midi kit (Qiagen, Barcelona, Spain) and was digested with DNase I (RNase-Free DNase set, Qiagen). First-strand cDNA was synthesized using an equal amount of total RNA with a High
Capacity RNA-to-cDNA Kit (Applied Biosystems, Madrid, Spain). Real-time quantitative PCR was performed in a final volume of 20 µL, which contained 10 ng of reverse-transcribed cDNA, 10 µL of 2× TaqMan Fast Universal PCR Master Mix (Applied Biosystems) and 1 µL TaqMan Assay predesigned by Applied Biosystems for the detection of IL-17A, IL-6, resistin, lipocalin-2, adiponectin, TNF receptor (R) II and GAPDH, which was used as housekeeping gene. All reactions were performed in triplicate and were carried out in 96-well plates using the 7900HT Fast Real-Time PCR System (Applied Biosystems). The mRNA expression for each gene and sample was calculated using the recommended $2^{-\Delta\Delta C_t}$ method.

4.4. IL-17A and Adipo/Cytokine Serum Levels

Circulating levels of IL-17A (Enzo Life Sciences, Farmingdale, NY, USA) and several adipo/cytokines—IL-6 (Quantikine, R&D Systems, Minneapolis, MN, USA), adiponectin (EMD Millipore, St. Charles, MI, USA), resistin (BioVendor, Brno, Czech Republic), lipocalin-2 (R&D Systems, Minneapolis, MN, USA) and TNFRII (AssayPro, St. Charles, IL, USA)—were measured in duplicate using enzyme-linked immunosorbent assays (ELISA) following the manufacturer’s instructions. The IL-17A assay sensitivity was 0.201 pg/mL, and intra-assay and inter-assay coefficients of variation (CV) were 5.4% and 9.4%, respectively. IL-6 assay sensitivity was 0.039 pg/mL, and intra-assay and inter-assay CV were 7.4% and 7.8%, respectively. Adiponectin assay sensitivity was 0.2 ng/mL, and intra-assay and inter-assay CV were 3.4% and 5.7%, respectively. Resistin assay sensitivity was 0.012 ng/mL, and intra-assay and inter-assay CV were 5.9% and 7.6%, respectively. Lipocalin-2 assay sensitivity was 0.012 ng/mL, and intra-assay and inter-assay CV were 3.7% and 6.5%, respectively. Finally, the TNFRII assay sensitivity was 0.1 ng/mL and the inter-assay and intra-assay coefficients of variation were less than 3.2% and 3.3%, respectively.

4.5. Statistical Analysis

All of the values reported were analyzed using the SPSS/PCC statistical package for Windows (v.20.0; Chicago, IL, USA). Differences between groups were calculated using Student’s $t$-test. The strength of association between variables was calculated using Pearson’s method for parametric variables and Spearman’s $r$ correlation test for non-parametric contrasts. $p$-values $< 0.05$ were considered to be statistically significant. Data are expressed as the mean ± SD.

5. Conclusions

In conclusion, IL-17A mRNA expression was almost undetectable in normal-weight controls in both VAT and SAT tissues. However, IL-17A expression in visceral adipose tissue is increased in morbidly obese women and was associated with IL-6, lipocalin-2 and resistin expression in VAT. These findings confirm that there is a link between obesity and innate immunity in low-grade chronic inflammation in morbidly obese women. Further studies of IL-17A circulating levels are needed to understand these controversial results.
Acknowledgments

This study was supported by the Ministerio de Ciencia e Innovación of the government of Spain (Grant Number SAF 2008-02278, to Cristóbal Richart), the Fondo de Investigación Sanitaria (Grant Number PS09/01778 to Teresa Auguet and PI13/00468 to Teresa Auguet), the Agència de Gestió d’Ajuts Universitaris de Recerca (AGAUR 2009 SGR 959 to Cristóbal Richart), the Grup de Recerca en Medicina Aplicada URV (2010 PFR-URV-B2-14 to Cristóbal Richart) and the Fundación Biociencia.

Author Contributions

Teresa Auguet and Fernando Zapata-Gonzalez participated in the design of the study, in the analysis and interpretation of data and were involved in drafting the manuscript. Gemma Aragonès reviewed/editied the manuscript. Esther Guiu-Jurado, Alba Berlanga and Carmen Aguilar carried out the experimental work. Salomé Martinez and Joan Josep Sirvent are the pathologists. Andreu Martí, Fátima Sabench, Mercé Hernandez, Rosa Jorba and Daniel Del Castillo made substantial contributions to the conception and design of the study and to the acquisition of samples. Cristóbal Richart revised the draft and gave final approval for publication. The authors have all seen the final version.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

BMI, body mass index; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; MO, morbidly obese; IL-17A, interleukin-17A; IL-6, interleukin 6; HbA1c, glycosylated hemoglobin; HOMA2-IR, homeostasis model assessment of insulin resistance; HDL-C, high density lipoprotein; LDL-C, low density lipoprotein.

References

1. Knight, J.A. Diseases and disorders associated with excess body weight. *Ann. Clin. Lab. Sci.* **2011**, *41*, 107–121.
2. Sartipy, P.; Loskutoff, D.J. Expression profiling identifies genes that continue to respond to insulin in adipocytes made insulin-resistant by treatment with tumor necrosis factor-alpha. *J. Biol. Chem.* **2003**, *278*, 52298–52306.
3. Steppan, C.M.; Bailey, S.T.; Bhat, S.; Brown, E.J.; Banerjee, R.R.; Wright, C.M.; Patel, H.R.; Ahima, R.S.; Lazar, M.A. The hormone resistin links obesity to diabetes. *Nature* **2001**, *409*, 307–312.
4. Cramer, T.; Johnson, R.S. A novel role for the hypoxia inducible transcription factor HIF-1alpha: Critical regulation of inflammatory cell function. *Cell Cycle* **2003**, *3*, 92–93.
5. Ozcan, U.; Cao, Q.; Yilmaz, E.; Lee, A.H.; Ikawoshi, N.N.; Ozdelen, E.; Tuncman, G.; Görgün, C.; Glimcher, L.H.; Hotamisligil, G.S. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science* **2004**, *306*, 457–461.
6. Johnson, A.M.; Olefsky, J.M. The origins and drivers of insulin resistance. *Cell* 2013, 152, 673–684.
7. Lee, J.; Ozcan, U. Unfolded protein response signaling and metabolic diseases. *J. Biol. Chem.* 2014, 289, 1203–1211.
8. Hotamisligil, G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. *Cell* 2010, 140, 900–917.
9. Hotamisligil, G.S.; Shargill, N.S.; Spiegelman, B.M. Adipose expression of tumor necrosis factor–alpha: Direct role in obesity-linked insulin resistance. *Science* 1993, 259, 87–91.
10. Shoelson, S.E.; Lee, J.; Goldfine, A.B. Inflammation and insulin resistance. *J. Clin. Investig.* 2006, 116, 1793–1801.
11. Olefsky, J.M.; Glass, C.K. Macrophages, inflammation, and insulin resistance. *Annu. Rev. Physiol.* 2010, 72, 219–246.
12. Weisberg, S.P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R.L.; Ferrante, A.W., Jr. Obesity is associated with macrophage accumulation in adipose tissue. *J. Clin. Investig.* 2003, 112, 1796–1808.
13. Auguet, T.; Guiu-Jurado, E.; Berlanga, A.; Terra, X.; Martinez, S.; Porras, J.A.; Ceausu, A.; Sabench, F.; Hernandez, M.; Aguilar, C.; *et al.* Downregulation of lipogenesis and fatty acid oxidation in the subcutaneous adipose tissue of morbidly obese women. *Obesity* 2014, 22, 2032–2038.
14. Ortega Martinez de Victoria, E.; Xu, X.; Koska, J.; Francisco, A.M.; Scalise, M.; Ferrante, A.W., Jr.; Krakoff, J. Macrophage content in subcutaneous adipose tissue: Associations with adiposity, age, inflammatory markers, and whole-body insulin action in healthy Pima Indians. *Diabetes* 2009, 58, 385–393.
15. Hummasti, S.; Hotamisligil, G.S. Endoplasmic reticulum stress and inflammation in obesity and diabetes. *Circ. Res.* 2010, 107, 579–591.
16. Kintscher, U.; Hartge, M.; Hess, K.; Foryst-Ludwig, A.; Clemenz, M.; Wabitsch, M.; Fischer-Posovszky, P.; Barth, T.F.; Dragun, D.; Skurk, T.; *et al.* T-lymphocyte infiltration in visceral adipose tissue: A primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. *Arterioscler. Thromb. Vasc. Biol.* 2008, 28, 1304–1310.
17. Liu, J.; Divoux, A.; Sun, J.; Zhang, J.; Clement, K.; Glickman, J.N.; Sukhova, G.K.; Wolters, P.J.; Du, J.; Gorgun, C.Z.; *et al.* Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. *Nat. Med.* 2009, 15, 940–945.
18. Ohmura, K.; Ishimori, N.; Ohmura, Y.; Tokuhara, S.; Nozawa, A.; Horii, S.; Andoh, Y.; Fujii, S.; Iwabuchi, K.; Onoe, K.; *et al.* Natural killer T–cells are involved in adipose tissue inflammation and glucose intolerance in diet induced obese mice. *Arterioscler. Thromb. Vasc. Biol.* 2010, 30, 193–199.
19. Sultan, A.; Strodthoff, D.; Robertson, A.K.; Paulsson-Berne, G.; Fauconnier, J.; Parini, P.; Ryden, M.; Thierry-Mieg, N.; Johansson, M.E.; Chibal, A.V.; *et al.* T cell-mediated inflammation in adipose tissue does not cause insulin resistance in hyperlipidemic mice. *Circ. Res.* 2009, 104, 961–968.
20. Afzali, B.; Lombardi, G.; Lechler, R.I.; Lord, G.M. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. *Clin. Exp. Immunol.* 2007, 148, 32–46.
21. Zúñiga, L.A.; Shen, W.J.; Joyce-Shaikh, B.; Pyatnova, E.A.; Richards, A.G.; Thom, C.; Andrade, S.M.; Cua, D.J.; Kraemer, F.B.; Butcher, E.C. IL-17A regulates adipogenesis, glucose homeostasis, and obesity. *J. Immunol.* 2010, 185, 6947–6959.

22. Sumarac-Dumanovic, M.; Stevanovic, D.; Ljubic, A.; Jorga, J.; Simic, M.; Stamenkovic-Pejkovic, D.; Starcevic, V.; Trajkovic, V.; Micic, D. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. *Int. J. Obes.* 2009, 33, 151–156.

23. Pini, M.; Fantuzzi, G. Enhanced production of IL-17A during zymosan-induced peritonitis in obese mice. *J. Leukoc. Biol.* 2010, 87, 51–58.

24. Magalhaes, I.; Pingris, K.; Poitou, C.; Bessoles, S.; Ventecelef, N.; Kiat, B.; Beaudoin, L.; da Silva, J.; Allatif, O.; Rossjohn, J.; et al. Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. *J. Clin. Investig.* 2015, 125, 1752–1762.

25. Dalmas, E.; Ventecelef, N.; Caer, C.; Poitou, C.; Cremer, I.; Aron-Wisnewsky, J.; Lacroix-Desmazes, S.; Bayry, J.; Kaveri, S.V.; Clément, K.; et al. T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: Relevance to obesity and type 2 diabetes. *Diabetes* 2014, 63, 1966–1977.

26. Fabbrini, E.; Cella, M.; McCartney, S.A.; Fuchs, A.; Abumrad, N.A.; Pietka, T.A.; Chen, Z.; Finck, B.N.; Han, D.H.; Magkos, F.; et al. Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. *Gastroenterology* 2013, 145, 366–374.

27. Carolan, E.; Tobin, L.M.; Mangan, B.A.; Corrigan, M.; Gaoatwe, G.; Byrne, G.; Geoghegan, J.; Cody, D.; O’Connell, J.; Winter, D.C.; et al. Altered distribution and increased IL-17 production by mucosal-associated invariant T cells in adult and childhood obesity. *J. Immunol.* 2015, 194, 5775–5780.

28. Fantuzzi, G. Central obesity: Measurement and metabolic effects. *Diabetes Rev.* 1997, 5, 8–20.

29. Després, J.P.; Lemieux, I. Abdominal obesity and metabolic syndrome. *Nature* 2006, 444, 881–887.

30. Onishi, R.M.; Gaffen, S.L. Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease. *Immunology* 2010, 129, 311–321.
37. Ahmed, M.; Gaffen, S.L. IL-17 in obesity and adipogenesis. *Cytokine Growth Factor Rev.* 2010, 21, 449–453.
38. Gaffen, S.L. Structure and signalling in the IL-17 receptor family. *Nat. Rev. Immunol.* 2009, 9, 556–567.
39. Harrington, L.E.; Hatton, R.D.; Mangan, P.R.; Murphy, K.M.; Weaver, C.T. Interleukin-17 producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. *Nat. Immunol.* 2005, 6, 1123–1132.
40. Park, H.; Li, Z.; Yang, X.O.; Chang, S.H.; Nurieva, R.; Wang, Y.H.; Wang, Y.; Hood, L.; Zhu, Z.; Tian, Q.; et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *Nat. Immunol.* 2005, 6, 1133–1141.
41. Ruddy, M.J.; Wong, G.C.; Liu, X.K.; Yamamoto, H.; Kasayama, S.; Kirkwood, K.L.; Gaffen, S.L. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer–binding protein family members. *J. Biol. Chem.* 2004, 279, 2559–2567.
42. Shen, F.; Ruddy, M.J.; Plamondon, P.; Gaffen, S.L. Cytokines link osteoblasts and inflammation: Microarray analysis of interleukin-17 and TNF-alpha-induced genes in bone cells. *J. Leukoc. Biol.* 2005, 77, 388–399.
43. Auguet, T.; Quintero, Y.; Terra, X.; Martínez, S.; Lucas, A.; Pellitero, S.; Aguilar, C.; Hernández, M.; del Castillo, D.; Richart, C. Upregulation of lipocalin 2 in adipose tissues of severely obese women: Positive relationship with proinflammatory cytokines. *Obesity* 2011, 19, 2295–2300.
44. Guo, H.; Jin, D.; Chen, X. Lipocalin 2 is a regulator of macrophage polarization and NF-κB/STAT3 pathway activation. *Mol. Endocrinol.* 2014, 28, 1616–1628.
45. Zhang, J.; Wu, Y.; Zhang, Y.; Leroith, D.; Bernlohr, D.A.; Chen, X. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. *Mol. Endocrinol.* 2008, 22, 1416–1426.
46. Terra, X.; Auguet, T.; Quesada, I.; Aguilar, C.; Luna, A.M.; Hernández, M.; Sabench, F.; Porras, J.A.; Martínez, S.; Lucas, A.; et al. Increased levels and adipose tissue expression of visfatin in morbidly obese women: The relationship with pro-inflammatory cytokines. *Clin. Endocrinol.* 2012, 77, 691–698.
47. Al-Suhaimi, E.A.; Shehzad, A. Leptin, resistin and visfatin: The missing link between endocrine metabolic disorders and immunity. *Eur. J. Med. Res.* 2013, 18, 12.
48. Witowski, J.; Ksiazek, K.; Jörres, A. Interleukin-17: A mediator of inflammatory responses. *Cell. Mol. Life Sci.* 2004, 61, 567–579.
49. De Angulo, A.; Faris, R.; Daniel, B.; Jolly, C.; de Graffenried, L. Age-related increase in IL-17 activates pro-inflammatory signaling in prostate cells. *Prostate* 2015, 75, 449–462.
50. Xuan, M.L.; Lu, C.J.; Han, L.; Xiang, Y. Circulating levels of inflammatory cytokines in patients with psoriasis vulgaris of different Chinese medicine syndromes. *Chin. J. Integr. Med.* 2015, 21, 108–114.
51. HOMA Calculator (Version 2.2.2). Available online: http://www.dtu.ox.ac.uk (accessed on 1 May 2010).

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).